Sarepta executes licensing agreement for gene therapy program from Nationwide Childrens Hospital to treat limbgirdle muscular dystrophy type 2A Today Sarepta announced that upon completion of a number of preclinical and safety studies the Company executed its licensing agreement to an investigational gene therapy candidate calpain 3 CAPN3 to treat limbgirdle muscular dystrophy type 2A LGMD2A